CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 228 enrolled
Drug / intervention
PF 04457845 +1 moredrug
Likely dose
PF 04457845 4mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03386487
NCT03386487Phase 2Completed
CompareCT.gov

A Phase 2B, 8-week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety and Tolerability of the Fatty Acid Amide Hydrolase (FAAH) Inhibitor PF-04457845 in Adults With DSM5 Current Cannabis Use Disorder (CUD)

Yale University·interventional·Posted Dec 29, 2017·Updated Feb 14, 2024

In Brief

A Phase 2 clinical trial evaluating PF 04457845 and Placebo Oral Tablet for Cannabis Use Disorder. Completed, enrolled 228 participants across 4 sites.

Detailed Summary

A Phase 2B, 8-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Tolerability of the Fatty Acid Amide Hydrolase (FAAH) Inhibitor PF-04457845 in Adults with DSM-5 Current Cannabis Use Disorder (CUD)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCannabis Use Disorder
CountriesUnited States
CollaboratorsColumbia University, Johns Hopkins University, Medical University of South Carolina, National Institute on Drug Abuse (NIDA)

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedDec 29, 2017
Enrollment StartJan 14, 2019
Primary CompletionJul 25, 2022
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 8.5 years ago

Interventions

PF 04457845drug

Study medication will be administered at 4mg by mouth daily for eight weeks.

Placebo Oral Tabletdrug

Placebo comparator will be administered by mouth daily for eight weeks.